Eclipsebio's New Assay Aims to Solve RNA Therapy’s Quality Control Puzzle

SAN DIEGO, CA – September 01, 2026 – In the high-stakes world of RNA therapeutics, a field supercharged by the success of mRNA vaccines, the race is on to develop the next wave of medicines for everything from cancer to rare genetic disorders. But behind the headline-grabbing breakthroughs lies a complex and often overlooked challenge: ensuring the quality and integrity of the RNA molecules at the heart of these drugs. Today, San Diego-based Eclipse Bioinnovations, Inc. (Eclipsebio) announced a major step toward solving this puzzle with the launch of eSTRAND RNA QC™, a new analytical tool designed to give drug developers a far clearer picture of their therapeutic candidates.

The new assay leverages nanopore-based direct RNA sequencing to provide a multi-faceted quality report in a single run. For an industry projected to be worth over $40 billion by the next decade, where speed and accuracy are paramount, such an innovation isn't just an incremental improvement—it's a potential game-changer for the entire development pipeline.

The Quality Control Bottleneck in RNA Therapeutics

The promise of RNA-based medicine rests on a deceptively simple premise: deliver a precise genetic message into the body to produce a therapeutic protein or silence a disease-causing gene. The reality, however, is that RNA is an inherently fragile and complex molecule. Its efficacy and safety depend on a host of structural features being perfectly in place. Any deviation—a shortened protective tail, an incorrect chemical cap, or the presence of unwanted byproducts—can render a billion-dollar drug candidate ineffective or, worse, unsafe.

For years, drug developers have relied on a patchwork of traditional analytical methods to assess their RNA products. Techniques like gel electrophoresis, capillary electrophoresis, and quantitative PCR provide valuable but often limited snapshots. These methods typically measure one attribute at a time, forcing researchers to run multiple, time-consuming tests to build a composite view of their RNA's quality.

More critically, many of these older techniques are indirect. They often require the RNA to be converted into more stable complementary DNA (cDNA) and amplified, a process that can introduce biases and erase crucial information about the native RNA molecule. This fragmented, low-resolution picture leaves developers making critical manufacturing decisions with incomplete data. As one industry analyst noted, it’s like trying to assemble a complex engine while only being able to inspect one part at a time, without seeing how they all fit together.

A Multi-Attribute Solution in a Single Run

Eclipsebio's eSTRAND RNA QC™ is designed to replace this fragmented process with a single, comprehensive analysis. The technology's core advantage is its use of direct RNA sequencing (DRS) powered by nanopore technology. Instead of being chopped up and converted, each full-length RNA molecule is threaded directly through a microscopic pore. As it passes through, the system reads its unique electrical signature, decoding the sequence and its modifications in real-time.

This approach allows eSTRAND RNA QC™ to simultaneously measure multiple critical quality attributes that are vital for therapeutic function. These include:

• RNA Identity: Confirming the sequence is 100% correct.
• Poly(A) Tail Length: This tail at the end of an mRNA molecule is crucial for its stability and how long it can produce protein. Direct sequencing measures its full, native length, a feat difficult for other methods.
• Capping Efficiency: The "cap" at the start of the molecule is essential for initiating protein production. The assay quantifies how many molecules are properly capped.
• Fragmentation Hotspots: Identifying any points of weakness where the RNA is prone to breaking.
• Double-Stranded RNA (dsRNA): Detecting this potential impurity, which can trigger an unwanted immune response in patients.

By delivering this holistic view in one go, the assay promises to dramatically cut down on the time and resources spent on quality control. "Low-resolution, single-dimensional insights from traditional characterization assays are not sufficient for today's drug development standards," said Eclipsebio Co-Founder and CEO Peter Chu, Ph.D., in the company's announcement. "eSTRAND RNA QC provides essential multi-attribute testing to provide partners the full scope of their RNA therapeutic quality."

Eclipsebio's Strategic Play in a Multi-Billion Dollar Market

The launch of eSTRAND RNA QC™ is more than just a new product; it's a calculated strategic move by Eclipsebio to establish itself as a dominant force in a critical niche of the burgeoning RNA therapeutics market. While giants like Illumina and Thermo Fisher command the broader sequencing landscape, Eclipsebio is targeting a specific, high-value pain point where its specialized expertise can provide a distinct advantage.

The market is ripe for such a solution. With the RNA therapeutics market expected to grow at a compound annual rate exceeding 17%, the demand for robust, efficient, and regulatory-friendly quality control tools is exploding. Drug developers are under immense pressure to accelerate timelines while simultaneously meeting increasingly stringent demands from bodies like the FDA for comprehensive product characterization.

This new assay fits neatly into Eclipsebio's broader vision of being an end-to-end partner in RNA drug development. The company already offers an integrated platform called eCOMPASS, which combines AI-powered sequence design with other analytical services like eCLIP and eSHAPE to de-risk therapeutic programs from the earliest stages. By adding a powerful, late-stage quality control tool, Eclipsebio strengthens its value proposition, offering support across the entire development lifecycle—from digital design to preclinical manufacturing analytics.

The Broader Impact: Accelerating the Next Wave of Medicine

Beyond the technical specifications and market strategy, the true significance of innovations like eSTRAND RNA QC™ lies in their potential to accelerate the delivery of life-changing medicines to patients. By providing clearer, faster, and more comprehensive data, the tool empowers scientists to make better decisions, optimize their manufacturing processes, and move promising candidates into the clinic with greater confidence.

This streamlining of the development "back-end" is crucial. The faster a company can iterate on its RNA design and production, the faster it can advance its clinical program. This acceleration could prove vital for therapies targeting aggressive cancers, rapidly progressing neurological disorders, or future pandemic threats.

Ultimately, the story of innovation in the modern economy is not just about the final product that grabs headlines. It’s also about the foundational tools and platforms that enable those breakthroughs. By addressing the fundamental challenge of quality control, Eclipsebio is providing a critical piece of infrastructure for the entire RNA therapeutics ecosystem, helping to ensure that the next generation of genetic medicines is not only powerful but also safe, consistent, and delivered to patients as quickly as possible.